2-214728831-C-T
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BP4_ModerateBP6BS2_Supporting
The NM_000465.4(BARD1):c.2179G>A(p.Asp727Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,614,068 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000465.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152182Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.0000438 AC: 11AN: 251342Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135834
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1461886Hom.: 0 Cov.: 32 AF XY: 0.0000110 AC XY: 8AN XY: 727242
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152182Hom.: 1 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74352
ClinVar
Submissions by phenotype
not provided Uncertain:3
- -
In the published literature, this variant has been reported along with a pathogenic BRAC2 variant in an individual with hypersensitivity to ionizing radiation (PMID: 34153142 (2021)). It has also been reported as a somatic variant detected in a stomach cancer tissue specimen (PMID: 29292755 (2017)). The frequency of this variant in the general population, 0.00025 (9/35430 chromosomes in Latino/Admixed American subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
This variant is denoted BARD1 c.2179G>A at the cDNA level, p.Asp727Asn (D727N) at the protein level, and results in the change of an Aspartic Acid to an Asparagine (GAT>AAT). This variant has not, to our knowledge, been published in the literature as a pathogenic or benign germline variant. BARD1 Asp727Asn was not observed at a significant allele frequency in large population cohorts (Lek 2016). BARD1 Asp727Asn is located in the BRCT2 domain (Fox 2008, UniProt). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available information, it is unclear whether BARD1 Asp727Asn is pathogenic or benign. We consider it to be a variant of uncertain significance. -
Familial cancer of breast Uncertain:1Benign:1
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 727 of the BARD1 protein (p.Asp727Asn). This variant is present in population databases (rs730881424, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with BARD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 182054). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The asparagine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
The p.D727N variant (also known as c.2179G>A), located in coding exon 11 of the BARD1 gene, results from a G to A substitution at nucleotide position 2179. The aspartic acid at codon 727 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at